It has been demonstrated recently in several solid tumors that thrombocytosis at diagnosis may correlate with tumor invasion, metastatic progression and worse outcome. Several details of the pathomechanism of the relationship of thrombocytosis and cancer have been elucidated; however, the complete process is not clearly understood. Several hypotheses have been proposed. Recently, it was suggested that in ovarian cancer elevated IL-6 production by the tumor may induce increased megakaryopoiesis via hepatic thrombopoietin production leading to thrombocytosis. The importance of the prognostic power of elevated platelet count is still debated in gastrointestinal cancer. The aims of this review were to evaluate the prognostic significance of thrombocytosis in gastrointestinal tumors, to see whether clinical practice confirmed the hypotheses and to reveal the causes of the inconsistent findings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/09537104.2016.1170112 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background/aim: Ovarian cancer remains a major cause of death in women worldwide, mainly due to late diagnosis and the lack of a reliable screening test for early detection of the disease. In this context, attention has been focused on the identification of other prognostic factors that might allow a better identification of cases with worse long-term outcome.
Patients And Methods: Data of patients who underwent cytoreductive surgery between 2014-2019 were retrospectively reviewed and 57 patients were considered eligible for this study.
Leukocytosis and thrombocytosis after splenectomy: expected finding, infection, or something else: a case report.
J Med Case Rep
October 2024
Division of Trauma, Burns and Surgical Critical Care, Department of Surgery, University of California, Irvine Medical Center, 3800 Chapman Ave, Suite 6200, Orange, Irvine, CA, 92868-3298, USA.
Article Synopsis
- Leukocytosis and thrombocytosis often occur after splenectomy, complicating the detection of infections in blunt trauma patients; a specific platelet count to white blood cell ratio can aid in this diagnosis but may overlook conditions like leukemia.
- A 53-year-old male developed abdominal issues after being assaulted and was found to have severe blood abnormalities post-surgery, prompting further investigation for a possible hematologic disorder.
- Ultimately, tests confirmed he had chronic myeloid leukemia, and he was treated with hydroxyurea followed by imatinib, highlighting the importance of thorough evaluation of blood counts post-splenectomy.
Recurrent, multisystem angioedema induced by 5-azacitidine.
J Oncol Pharm Pract
October 2024
Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA, USA.
Article Synopsis
- 5-azacitidine is a treatment for myelodysplastic syndrome (MDS) and certain myeloproliferative neoplasms (MPNs), but it can cause side effects like myelosuppression and nausea, with rare, serious allergic reactions.
- A case study describes a 71-year-old man with MDS/MPN who experienced repeated episodes of angioedema after starting 5-azacitidine, affecting various body areas and deemed causally linked to the medication.
- After discontinuing 5-azacitidine due to ongoing angioedema, the patient responded well to steroids and is now managing his blood condition with low-dose hydroxyurea, while the exact cause
Beyond the Gut: Exploring Cardiovascular Implications of Celiac Disease.
Cardiol Rev
September 2024
Department of medicine, Penn State Hershey Medical Center, PA.
Article Synopsis
- * There is an increasing link between CD and cardiovascular diseases (CVDs) like atherosclerosis and arrhythmia, attributed to factors like chronic inflammation and nutrient deficiencies.
- * The article reviews how CD may lead to different CVD outcomes, analyzing existing studies that show both positive and negative effects of CD on cardiovascular health.
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial.
Am J Hematol
August 2024
Department of Safety and Bioethics, Section of Pharmacology, Catholic University School of Medicine, Rome, Italy.
Article Synopsis
- People with essential thrombocythemia (ET) usually take low-dose aspirin once a day to avoid blood clots, but this isn't always effective because their platelet levels change quickly.
- A study tested if taking aspirin twice a day would work better and found that it did help lower certain blood markers and symptoms over 20 months.
- The results showed that twice-daily aspirin caused fewer major blood clots, didn't lead to significant bleeding problems, and made patients feel better overall compared to taking it once a day.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!